Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
“Pathogenic bacteria in the gut lumen” is a broad, non-canonical designation referring to any bacterial species residing within the intestinal lumen that have the capacity to cause disease. This term does not refer to a single molecular target or receptor, but to a heterogeneous group of microorganisms. Prominent examples include *Clostridioides difficile*, *Salmonella enterica*, *Escherichia coli* (particularly certain pathogenic strains), *Shigella*, and *Campylobacter* species[2][4][5]. These bacteria employ various virulence factors—such as toxins, secretion systems, and immune evasion strategies—to colonize the gut, invade or disrupt the mucosal barrier, outcompete the beneficial commensal flora, and induce host disease processes. Therapeutic approaches typically rely on broad-spectrum or targeted antibiotics, but these interventions must be carefully managed due to collateral effects on the wider gut microbiota and the risk of selecting for antibiotic resistance[5][6]. The diversity of these pathogens and their dynamic interaction with both the host and the commensal microbiota complicates both the diagnosis and therapy for their associated diseases. Strictly, “pathogenic bacteria in the gut lumen” is not a proper molecular or receptor-based therapeutic target in current biomedical taxonomy—it refers to an entire class of disease-causing organisms rather than a druggable molecule or protein[2][5][6][7].
Antibiotic inhibition of bacterial cell wall synthesis, inhibition of protein synthesis, disruption of DNA replication, competitive exclusion (probiotics), lysis by bacteriophages
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacterium in the gut lumen.